E-25 | Ultra-thin Everolimus-eluting Stents in Atherosclerotic Lesions: Three Years Follow-up with Subgroup Analysis of Ultra-long Lesions

Ultrathin, biodegradable polymer-coated everolimus-eluting stents for patients undergoing percutaneous coronary intervention: Final three-year results of the PERFORM-EVER registry

“…A registry of Tetrilimus EES on real-world patients also reported similar incidence of major adverse cardiovascular events at three-year follow-up in overall (9.1 %) as well as in patient with long coronary lesions (10.4 % in >40 mm lesion length). 19 For purpose of comparison, three-year rates of device-oriented clinical events (DoCE) for other ultrathin DES include—10.5 % with MiStent SES vs 11.5 % with Xience EES in DESSOLVE III trial 23 ; 8.1 % with Supraflex SES vs 9.4 % with Xience EES in TALENT trial 13 ; 8.2 % with Orsiro SES vs 13.6 % with Xience EES in BIOFLOW V trial 24 ; 6.7 % with Orsiro SES vs 7.5 % with Synergy EES in BIO-RESORT trial 25 ; and 9.0 % with Orsiro SES vs 9.1 % with Nobori biolimus-eluting stent in SORT OUT VII trial. 26 Similarly, T-FLEX registry ( n = 1203) reported 8.1 % TLF rate with Supraflex Cruz SES (ultrathin biodegradable polymer-coated stent with the LDZ link) in real-world Indian patients up to 3-year follow-up.…”

“… 26 Furthermore, the results of another real-world registry on Tetrilimus EES also reported similar incidence of definite or probable stent thrombosis in overall (0.4 %) and even in long lesion (>40 mm) subgroup (1.4 %) at three-year follow-up. 19 …”

“…The safety and effectiveness of Tetrilimus EES have previously been reported in several studies, 14 , 15 , 16 , 17 , 18 but there are inadequate long-term clinical data (>1 year after implantation) on this latest generation ultrathin DES. 19 Specifically, there is a need to establish whether Tetrilimus EES can overcome the limitations of earlier generation DES, like late in-stent restenosis and very late stent thrombosis. Therefore, we examined the final three-year clinical outcomes after implantation of Tetrilimus EES in real-world, unselected patients with coronary artery disease in the PERFORM-EVER registry.…”